NHS rolls out teplizumab immunotherapy to delay type 1 diabetes onset by three years

The NHS is rolling out teplizumab, an immunotherapy drug that delays the onset of type 1 diabetes by an average of three years in children and adults. The drug, also known as Tzield, works by reprogramming the immune system to stop it attacking insulin-producing cells. It will be